ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma. - Tabular View

Tracking Information
First Received Date ^ICMJE	July 2, 2002
Last Updated Date	March 14, 2007
Start Date ^ICMJE
Primary Completion Date
Current Primary Outcome Measures ^ICMJE
Original Primary Outcome Measures ^ICMJE
Change History	Complete list of historical versions of study NCT00040625 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE
Original Secondary Outcome Measures ^ICMJE

Descriptive Information
Brief Title ^ICMJE	ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
Official Title ^ICMJE
Brief Summary	This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
Detailed Description
Study Phase	Phase II
Study Type ^ICMJE	Expanded Access
Study Design ^ICMJE
Condition ^ICMJE	Mesothelioma
Intervention ^ICMJE	Drug: Pemetrexed Drug: Cisplatin
Study Arms / Comparison Groups
Publications *
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Approved for marketing
Enrollment ^ICMJE
Completion Date
Primary Completion Date
Eligibility Criteria ^ICMJE	Inclusion Criteria: Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery Prior chemotherapy for your disease is allowed Measurable lesion is not required Have a adequate performance status Sign an informed consent form Exclusion Criteria: You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study You are excluded from this trial if you have received radiation within the previous 2 weeks You are excluded from this trial if you are a candidates for curative surgery
Gender	Both
Ages	18 Years and older
Accepts Healthy Volunteers	No
Contacts ^ICMJE	Contact information is only displayed when the study is recruiting subjects
Location Countries ^ICMJE	United States, Brazil, Egypt, Saudi Arabia

Administrative Information
NCT ID ^ICMJE	NCT00040625
Responsible Party
Study ID Numbers ^ICMJE	6093, H3E-US-JMFE
Study Sponsor ^ICMJE	Eli Lilly and Company
Collaborators ^ICMJE
Investigators ^ICMJE
Information Provided By	Eli Lilly and Company
Verification Date	March 2007
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP